MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/13506129.2026.2651299

Медицинская библиотека · Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis · 2026

Transthyretin stabilizer therapy increases naturally-occurring antibodies in ATTR cardiomyopathy.

Settelmeier Stephan, Agranovski Daniel, Steinhardt Maximilian, Waydhas Sarah, Gering Ian, Cejka Vladimir, Morbach Caroline, Störk Stefan, Willbold Dieter, Küppers Ralf, Vogel Julia, Michel Lars, Carpinteiro Alexander, Reinhardt H Christian, Dodel Richard, Rassaf Tienush, Ross Alexander J, Hendgen-Cotta Ulrike B

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Amyloid transthyretin cardiomyopathy (ATTR-CM) results from extracellular deposition of misfolded transthyretin (TTR), causing progressive heart failure. Naturally-occurring antibodies (nAbs) targeting misfolded proteins exist in neurodegenerative disease, but their presence in ATTR-CM is unknown. The objective of this study is to determine whether nAbs against TTR (nAbsTTR) exist in humans and whether they are influenced by disease or its treatment.

METHODS

Serum from healthy donors, umbilical cord blood (UCB), and patients with ATTR-CM - both untreated and receiving TTR-stabilizing therapy - was analyzed for nAbsTTR using immunoassays, blotting, and binding studies. Functional activity was evaluated in a fibril formation assay.

RESULTS

nAbsTTR binding both native and amyloid TTR (ATTR) with high affinity (KD 30 nM/7 nM) were detected in healthy serum and UCB. NAbsTTR levels were significantly altered in ATTR-CM compared to controls: nAbsTTR (IgG) were higher while nAbsTTR (IgM) were lower. nAbsTTR of both subtypes significantly increased by 22% (p ≤ 0.05) in patients receiving TTR-stabilizing therapy. In vitro, nAbsTTR suppressed TTR fibril aggregation.

CONCLUSIONS

Naturally-occurring TTR-targeting antibodies are present from birth, modulated by disease and therapy, and inhibit fibril formation. These findings reveal an unrecognized immune mechanism with potential relevance for ATTR-CM pathogenesis and treatment.

Для цитирования: Settelmeier Stephan, Agranovski Daniel, Steinhardt Maximilian, Waydhas Sarah, Gering Ian, Cejka Vladimir, Morbach Caroline, Störk Stefan, Willbold Dieter, Küppers Ralf, Vogel Julia, Michel Lars, Carpinteiro Alexander, Reinhardt H Christian, Dodel Richard, Rassaf Tienush, Ross Alexander J, Hendgen-Cotta Ulrike B. Transthyretin stabilizer therapy increases naturally-occurring antibodies in ATTR cardiomyopathy.. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 2026. DOI: 10.1080/13506129.2026.2651299.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.